Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms

2017; Elsevier BV; Volume: 130; Issue: 26 Linguagem: Inglês

10.1182/blood-2017-05-784942

ISSN

1528-0020

Autores

Margaret Nieborowska-Skorska, Silvia Maifrede, Yashodhara Dasgupta, Katherine Sullivan, Sylwia Flis, Bac Viet Le, Martyna Solecka, Elizaveta Belyaeva, Lucia Kubovčáková, Morgan Nawrocki, Martin Kirschner, Huaqing Zhao, Josef T. Prchal, Katarzyna Piwocka, Alison R. Moliterno, Mariusz A. Wasik, Steffen Koschmieder, Anthony R. Green, Radek C. Skoda, Tomasz Skórski,

Tópico(s)

Chronic Myeloid Leukemia Treatments

Resumo

Key Points Ruxolitinib caused DNA repair defects and sensitized MPN stem and progenitor cells to PARP inhibitors. Quiescent and proliferating MPN cells were eliminated by ruxolitinib and olaparib plus or minus hydroxyurea.

Referência(s)